Search
Akoustis Technologies Ord Shs
AKTSAdd to Watchlist
24.010USD
-0.800-3.22%
Close 07-23 16:00（ET）Quotes delayed by 15 min
1.22BMarket Cap
LossP/E TTM
More Details of Akoustis Technologies Ord Shs Company
Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.
Akoustis Technologies Ord Shs Info
Ticker SymbolAKTS
Company nameAktis Oncology Inc
IPO dateJan 09, 2026
CEORoden (Matthew)
Number of employees117
Security typeOrdinary Share
Fiscal year-endJan 09
Address17 Drydock Avenue
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02210
Phone13026587581
Websitehttps://www.aktisoncology.com/
Ticker SymbolAKTS
IPO dateJan 09, 2026
CEORoden (Matthew)
Company Executives of Akoustis Technologies Ord Shs
Name
Name/Position
Position
Shareholding
Change
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
91.99K
-0.01%
Mr. Arthur E. Geiss, Ph.D.
Mr. Arthur E. Geiss, Ph.D.
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
--
--
Dr. Jerry D. Neal, Ph.D.
Dr. Jerry D. Neal, Ph.D.
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
--
--
Mr. Paul L. Feldman, Ph.D.
Mr. Paul L. Feldman, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Tyler Benedum, Ph.D.
Mr. Tyler Benedum, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Ms. Jill K. Frizzley
Ms. Jill K. Frizzley
Independent Director
Independent Director
--
--
Mr. Matthew R. Kahn, CPA
Mr. Matthew R. Kahn, CPA
Independent Director
Independent Director
--
--
Mr. Todd Foley
Mr. Todd Foley
Chairman of the Board of Director
Chairman of the Board of Director
--
-100.00%
Ms. Shulamit Ron-Bigger, Ph.D.
Ms. Shulamit Ron-Bigger, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Kyle D. Kuvalanka
Mr. Kyle D. Kuvalanka
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
91.99K
-0.01%
Mr. Arthur E. Geiss, Ph.D.
Mr. Arthur E. Geiss, Ph.D.
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
--
--
Dr. Jerry D. Neal, Ph.D.
Dr. Jerry D. Neal, Ph.D.
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
--
--
Mr. Paul L. Feldman, Ph.D.
Mr. Paul L. Feldman, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Tyler Benedum, Ph.D.
Mr. Tyler Benedum, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Ms. Jill K. Frizzley
Ms. Jill K. Frizzley
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Akoustis Technologies Ord Shs?
The top five shareholders of Akoustis Technologies Ord Shs are: Mr. Matthew (Matt) Roden, Ph.D.
How many institutions hold shares of Akoustis Technologies Ord Shs (AKTS)?
As of 2026Q1, 195 institutions hold shares of Akoustis Technologies Ord Shs, with a combined market value of approximately 27.52M, accounting for 51.47% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1127277.00.